Forward Pharma Makes Debut At Annual International High-Tech Fair

On November 11, 2020, the 22nd China International High-Tech Fair ("High-Tech Fair") opened at the Shenzhen Convention and Exhibition Center (Futian). The theme of this year's fair is "Technology changes life, innovation drives development", adopting a combination of online and offline exhibition modes, attracting more than 3,300 domestic and foreign exhibitors, nearly 10,000 projects exhibited, and over 140 activities held.

The development of technology innovation products and enterprises cannot be separated from capital support. As an important core engine of early investment and technological innovation in Shenzhen, Shenzhen Angel Investment Guidance Fund Co., Ltd. ("Angel Mother Fund") established the "Shenzhen Angel Mother Fund High-Tech Exhibition". Fosun Pharma, one of the excellent projects of the Angel Mother Fund, showcased its independently developed targeted therapy drug FWD1509 for non-small cell lung cancer at booth B02-07 in Hall 9.

FWD1509 is a lung cancer targeted therapy drug with core independent intellectual property rights independently developed by Forward Pharma, which targets two major unmet clinical needs, EGFR exon 20 insertion mutation and lung cancer brain metastasis, and is expected to become a heavyweight global first-in-class innovative drug independently developed by Shenzhen in the future. FWD1509 has been submitted for clinical trials in China and the United States and will soon start international Phase I clinical trials in 2021Q1. This product has carried out patent layouts for independent core intellectual property rights in both China and internationally, and in addition to the huge potential in the Chinese market, it will enter major international markets such as the United States, EU, and Japan in the future.